Etilefrine

Identification

Name
Etilefrine
Accession Number
DB08985
Description

Etilefrine is an adrenergic agonist that appears to interact with beta-2 and some alpha adrenergic receptors. It has been used as a vasoconstrictor agent.

Type
Small Molecule
Groups
Approved, Withdrawn
Structure
Thumb
Weight
Average: 181.2316
Monoisotopic: 181.110278729
Chemical Formula
C10H15NO2
Synonyms
  • Etilefrina
  • Etilefrine
  • Etilefrinum
External IDs
  • S 40032
  • S 40032-7

Pharmacology

Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbaloparatideThe risk or severity of adverse effects can be increased when Etilefrine is combined with Abaloparatide.
AcebutololThe therapeutic efficacy of Etilefrine can be decreased when used in combination with Acebutolol.
AceclofenacThe risk or severity of hypertension can be increased when Aceclofenac is combined with Etilefrine.
AcemetacinThe risk or severity of hypertension can be increased when Etilefrine is combined with Acemetacin.
Acetylsalicylic acidThe risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Etilefrine.
AclidiniumThe risk or severity of Tachycardia can be increased when Aclidinium is combined with Etilefrine.
AdenosineThe risk or severity of Tachycardia can be increased when Adenosine is combined with Etilefrine.
AlclofenacThe risk or severity of hypertension can be increased when Etilefrine is combined with Alclofenac.
AlfentanilThe risk or severity of hypertension can be increased when Alfentanil is combined with Etilefrine.
AlfuzosinThe therapeutic efficacy of Etilefrine can be decreased when used in combination with Alfuzosin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Product Ingredients
IngredientUNIICASInChI Key
Etilefrine hydrochlorideZBI6Q5FH3S943-17-9KTNROWWHOBZQGK-UHFFFAOYSA-N
International/Other Brands
Apocretin / Circupon / Effontil / Effortil / Effortilvet / Eti-Puren / Kertasin / Phetanol / Phetasin / Tonus-Forte / Updormin

Categories

ATC Codes
C01CA51 — Etilefrine, combinationsC01CA01 — Etilefrine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as 1-hydroxy-4-unsubstituted benzenoids. These are phenols that are unsubstituted at the 4-position.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenols
Sub Class
1-hydroxy-4-unsubstituted benzenoids
Direct Parent
1-hydroxy-4-unsubstituted benzenoids
Alternative Parents
Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Benzene and substituted derivatives / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols
Substituents
1,2-aminoalcohol / 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / Alcohol / Amine / Aralkylamine / Aromatic alcohol / Aromatic homomonocyclic compound / Hydrocarbon derivative / Monocyclic benzene moiety
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
ZB6F8MY53V
CAS number
709-55-7
InChI Key
SQVIAVUSQAWMKL-UHFFFAOYSA-N
InChI
InChI=1S/C10H15NO2/c1-2-11-7-10(13)8-4-3-5-9(12)6-8/h3-6,10-13H,2,7H2,1H3
IUPAC Name
3-[2-(ethylamino)-1-hydroxyethyl]phenol
SMILES
CCNCC(O)C1=CC=CC(O)=C1

References

Synthesis Reference

British Patent 1,358,973.

General References
Not Available
KEGG Drug
D07931
PubChem Compound
3306
PubChem Substance
310264946
ChemSpider
3190
BindingDB
97154
RxNav
4169
ChEBI
91518
ChEMBL
CHEMBL86882
Wikipedia
Etilefrine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionOral5 mg/mL
Capsule, extended release25 MG
Injection, solution10 MG/1ML
Injection, solutionIntramuscular; Subcutaneous15 mg/ml
SolutionOral7.5 mg/mL
Solution / dropsOral7.5 MG/ML
Tablet5 MG
Tablet5 mg/1
Solution / drops7.5 mg/ml
SolutionIntramuscular; Intravenous; Subcutaneous10 mg
Tablet, coatedOral5 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)208-209British Patent 1,358,973.
Predicted Properties
PropertyValueSource
Water Solubility13.8 mg/mLALOGPS
logP0.01ALOGPS
logP0.23ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)9.1ChemAxon
pKa (Strongest Basic)9.73ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area52.49 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity52 m3·mol-1ChemAxon
Polarizability20.33 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-05no-3900000000-dc75520c0fb8e17d3ef6

Drug created on June 10, 2014 11:55 / Updated on August 13, 2020 01:04

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates